, glycoprotein E adjuvanted with alum, or glycoprotein E adjuvanted with AS01 formulations containing lower amounts of the MPL and QS21 immuno- stimulants. Therefore, although the small number of HZ/su recipients with herpes zoster
in our study may prove insufficient to define an immunologic correlate of protection, future analyses of HZ/su immunogenicity will be of interest in explaining how an immune response targeting a single VZV antigen provides age- independent protection against herpes zoster in older adults.